NanoPass Technologies develops painless intradermal delivery solutions for vaccines and large molecules.

Its IP-backed product, the MicronJet, is a hollow microneedle device.The company’s microneedles are manufactured using microelectromechanical systems (MEMS) technology and made of pure silicon crystals.

The use of MEMS technology has enabled the creation of elaborate miniature devices with mechanical stability and structural precision.

NanoPass MicroPyramid arrays are manufactured in industrial clean rooms using a high-precision production process.NanoPass Technologies has conducted an intradermal pandemic flu vaccine study and additional seasonal flu studies demonstrating equivalent or superior immunogenicity to standard delivery using only 20% of the dose.In February 2017, NanoPass Technologies announced that it had signed an agreement with the IDRI to develop an intradermal rvRNA-based Zika virus vaccine.